CAMBRIDGE Mass.--(BUSINESS WIRE)--Jun 5 2007 - JavelinPharmaceutica... Rylomine is one of three late stage drug development candidatesin ou...Top line data from the first of two pivotal post-surgical Phase3 clin...Orthopedic Surgeries ...According to the United States Department of Health and HumanServices...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - Javelin
Pharmaceuticals, Inc. (AMEX: JAV), a leading developer of novel
products for pain control, today announced that its Phase 2
multi-dose study of Rylomine was published in Pain Medicine, the
official journal of The American Academy of Pain Medicine. The
article, entitled, "Analgesic Efficacy and Safety of
Morphine-Chitosan Nasal Solution in Patients with Moderate to
Severe Pain Following Orthopedic Surgery", was recently made
available online and can found at the following link:
http://www.blackwell-synergy.com/toc/pme/0/0?.

"Rylomine is one of three late stage drug development candidates
in our pipeline that address large underserved markets for pain
management. It employs a patented formulation of intranasal
morphine in a simple disposable device that requires no programming
or special patient education," said, Dr. Daniel B. Carr, CEO and
CMO. "While still in development, Rylomine has potential to become
the non-invasive approach of choice for administering intermittent
doses of morphine for post-surgical pain in medically supervised
settings. Morphine is the reference standard for treatment of
post-surgical pain, as well as pain from trauma and diseases
including cancer."

Top line data from the first of two pivotal post-surgical Phase
3 clinical trials of Javelin's Rylomine is anticipated this
summer.

Orthopedic Surgeries

According to the United States Department of Health and Human
Services, orthopedic operations make up approximately 10% (7.4
million) of the 73.4 million ambulatory and in-patient surgical
procedures in the United States annually.

About Rylomine

Rylomine (intranasal morphine), is currently in Phase 3
development in the United States, for moderate-to-severe pain in
supervised healthcare settings. It employs the patented and
proprietary, Chysis(R) drug-delivery platform to adhere and
regularize the kinet
ics of morphine to and across the nasal mucosa.
Each nostril can hold only 150-200 ul of administered drug
candidate and requires approximately 15 minutes for the Rylomine to
clear the nasal passages. This provides potential for substantial
patient safety.

About Javelin Pharmaceuticals, Inc.

With US corporate headquarters in Cambridge, MA, and a European
office in Cambridge, UK, Javelin applies innovative proprietary
technologies to develop new drugs and improved formulations of
existing drugs to target unmet and underserved medical needs in the
pain management market. For additional information, please visit
the website at www.javelinpharmaceuticals.com.

Forward-looking Statement

This press release contains forward-looking statements. Such
statements are valid only as of today, and we disclaim any
obligation to update this information. These statements are subject
to known and unknown risks and uncertainties that may cause actual
future experience and results to differ materially from the
statements made. These statements are based on our current beliefs
and expectations as to such future outcomes. Drug discovery and
development involve a high degree of risk. Factors that might cause
such a material difference include, among others, uncertainties
related to the ability to attract and retain partners for our
technologies, the identification of lead compounds, the successful
preclinical development thereof, the completion of clinical trials,
the FDA (and foreign equivalent) review process and other
governmental regulation, our ability to obtain working capital, our
ability to successfully develop and commercialize drug candidates,
and competition from other pharmaceutical companies.

(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... Trends - Adhesion Type, Application, Usability - Forecast to 2025" ... , ... Market is poised to grow at a CAGR of around 3.2% ... market is witnessing include advancements in extracellular microelectrode arrays and intracellular ...

(Date:12/8/2016)... TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...

(Date:12/8/2016)... , Dec. 8, 2016 Pennsylvania Physician General ... Drug and Alcohol Programs Gary Tennis ... medications, known as benzodiazepines, developed with the help ... are medications that are frequently prescribed for anxiety ... are used with opioid pain medications, benzodiazepines pose ...

(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying record-breaking ... registration today for its 33rd Annual Issues & Research Conference, March 2-3, ... theme of the conference is “Persistent Challenges and New Opportunities: Using Research to ...

(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , a ... other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger to ... president of sales. , Litsinger joined Mirixa in 2008 after serving as ...

(Date:12/8/2016)... ... December 08, 2016 , ... STATEN ISLAND, N.Y., ... for adherence to the highest standards of trauma, maternity, cancer and chronic obstructive ... president and CEO, Dr. Daniel Messina. , Among the recognitions, the American College ...

(Date:12/8/2016)... ... December 08, 2016 , ... Healthcare is in flux. The ... for the mass media launching of story movements to highlight what's most unfair ... unfortunate experiences; such a movement can generate the network power to improve healthcare ...